Clinical trials: Phase I
Healthy Volunteer
Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib
to evaluate the effect of the PPI (rabeprazole) on the PK of a potential commercial tablet formulation of palbociclib
- Trial name
- NCT03220191
- Testing
- Palbociclib, Rabeprazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Multiple Myeloma
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
- Trial name
- NCT07490613
- Testing
- SHR-3836 administered as multiple doses.
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Tumor, Lymphoma
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Patients with advanced tumors diagnosed histologically or cytologically at the study center who were refractory to standard therapy or had relapsed received XNW5004 tablets
- Trial name
- NCT06558513
- Testing
- XNW5004 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Evopoint Biosciences Inc.
Solid Tumors
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
This study was to determine the maximum-tolerated dose (MTD) and/or the optimal biological dose (OBD) as well as the optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508 as monotherapy, with or…
- Trial name
- NCT03539484
- Testing
- RO7172508, Obinutuzumab, Tocilizumab
- Where
- 6 sites in Belgium, Canada and 2 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
X-Linked Retinitis Pigmentosa
Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
Phase 1 of the study is a dose escalation of the subretinal administration of AAV5-hRKp.RPGR vector to assess the safety of this vector in participants with XLRP caused by mutations in RPGR.
- Trial name
- NCT03252847
- Testing
- AAV5-RPGR
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 49 people
- Sponsor
- MeiraGTx UK II Ltd
Healthy Volunteers
A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects
This is a single center, non-randomized, open label Phase 1 study to determine the PK and absolute bioavailability of BIIB122 (DNL151) in 2 conditions: following a single, oral dose of BIIB122 (DNL151) and following consecutive…
- Trial name
- NCT05005338
- Testing
- BIIB122 (DNL151), [14C] BIIB122 ([14C] DNL151)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Biogen
Advanced Solid Cancer, Advanced Solid Tumor (Phase 1)
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects…
- Trial name
- NCT07123415
- Testing
- APX-343A, Pembrolizumab
- Where
- 3 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- Aptabio Therapeutics, Inc.
Lymphoma, Refractory Solid Tumors
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
The purpose of this study is to evaluate the safety and tolerability of ASP4132 and to determine the maximum tolerated dose and recommended phase 2 dose of ASP4132.
- Conditions
- Lymphoma, Refractory Solid Tumors, Advanced Cancer
- Trial name
- NCT02383368
- Testing
- ASP4132
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Astellas Pharma Global Development, Inc.
ER+ HER2- Advanced Breast Cancer
AZD9496 First Time in Patients Ascending Dose Study
This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer.
- Trial name
- NCT02248090
- Testing
- AZD9496
- Where
- 6 sites in United States, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Diabetic Foot Ulcer
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial (ALLO-ASC-DFU-101) for 23 months.
- Trial name
- NCT03183726
- Testing
- ALLO-ASC-DFU
- Volunteers
- 4 people
- Sponsor
- Anterogen Co., Ltd.
HIV Infections
A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS
To determine the safety and efficacy of zidovudine (AZT) treatment combined with syngeneic or HLA identical allogeneic lymphocyte transfer in the presence of interleukin 2 (IL-2) as a treatment for AIDS.
- Trial name
- NCT00002285
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
Neoplasms
Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Primary objectives of this study are to assess the safety and tolerability of BAY 1163877 in Japanese subjects with refractory, locally advanced or metastatic solid tumors and to characterize the PK of BAY 1163877
- Trial name
- NCT02592785
- Testing
- BAY1163877
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Bayer
Glioblastoma
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
BACKGROUND: Active immunotherapy of cancer is based on the premise that the vaccine raises a cytotoxic immune response to tumor-associated antigens, thereby destroying malignant cells without harming normal cells.
- Trial name
- NCT01403285
- Testing
- Cyclophosphamide, IMA950 plus GM-CSF, IMA950
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Immatics Biotechnologies GmbH
Chikungunya Fever, Chikungunya Virus
Trial of an Inactivated Chikungunya Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 2.5 mcg and 8 mcg of HydroVax-005 CHIKV vaccine given intramuscularly on Day 1 and Day…
- Conditions
- Chikungunya Fever, Chikungunya Virus, Chikungunya
- Trial name
- NCT06669208
- Testing
- HydroVax-005 CHIKV
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Najit Technologies, Inc.
Metastatic Prostate Cancer
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
This is a study of opevesostat in healthy adult male participants. The purpose of this study is to understand the absorption, distribution, metabolism, and elimination of opevesostat in humans, as well as its pharmacokinetics…
- Trial name
- NCT06566989
- Testing
- [¹⁴C]Opevesostat, Prednisone, Fludrocortisone
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Acute Stroke
Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke
This study is a first-in-human assessment of safety of using umbilical cord mesenchymal stem cells (UCMSCs) in patients with Acute Ischemic Stroke via a combination of intra arterial (IA) and intravenous (IV) stem cell…
- Trial name
- NCT04434768
- Testing
- UMSC01
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Advanced Solid Tumor
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose…
- Trial name
- MINOTAUR (NCT05147350)
- Testing
- RP-6306 (oral PKMYT1 inhibitor)
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 38 people
- Sponsor
- Debiopharm International SA
Healthy Volunteers
A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects
This is a Phase 1, open-label, randomized, parallel-group, single-dose study. Approximately 56 participants will be enrolled and randomized into 1 of the 2 treatment groups, with 28 participants in each treatment group as…
- Trial name
- NCT04528290
- Testing
- Ozanimod
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy
Drug Interaction Study of Isavuconazole and Cyclosporine
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of cyclosporine in healthy adult subjects.
- Trial name
- NCT01494597
- Testing
- isavuconazole, cyclosporine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.